A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

PHASE1RecruitingINTERVENTIONAL
Enrollment

345

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

May 25, 2029

Conditions
Neoplasms
Interventions
DRUG

RO7673396

RO7673396 will be administered as per the schedule specified in the protocol.

Trial Locations (18)

1010

RECRUITING

New Zealand Clinical Research - Auckland, Auckland

2010

RECRUITING

St Vincent's Hospital Sydney, Darlinghurst

3052

RECRUITING

Peter MacCallum Cancer Center, Parkville

8011

RECRUITING

New Zealand Clinical Research - Christchurch, Christchurch

10002

RECRUITING

National Taiwan University Hospital, Taipei

34232

RECRUITING

Florida Cancer Specialists - Sarasota (North Catttlemen Rd), Sarasota

70403

RECRUITING

National Cheng Kung University Hospital, Tainan City

91010

RECRUITING

City of Hope Comprehensive Cancer Center, Duarte

168583

RECRUITING

National Cancer Centre - 30 Hospital Blvd, Singapore

201315

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

430079

RECRUITING

Hubei Cancer Hospital, Wuhan

510060

RECRUITING

Sun yat-sen University Cancer Center, Guangzhou

510555

RECRUITING

Sun Yat-Sen University Cancer Center - Huangpu Campus, Guangzhou

06519-1110

RECRUITING

Smilow Cancer Hospital at Yale New Haven, New Haven

77030-3721

RECRUITING

MD Anderson Cancer Center, Houston

78229-4427

RECRUITING

South Texas Accelerated Research Therapeutics (START), San Antonio

M5G 2M9

RECRUITING

Princess Margaret Hospital, Toronto

Unknown

RECRUITING

Prince of Wales Hospital, Hong Kong

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY